BCM
CTIC

BlueCrest Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

BlueCrest Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-143,587
Closed -$560K – 2088
2018
Q1 		$560K Buy
+143,587
New +$505K 0.02% 708

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BlueCrest Capital Management's CTIC Position: Q2 2018 in Review

BlueCrest Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2018, closing a stake of 143,587 shares — an estimated $560K sold.

BlueCrest Capital Management first reported a position in CTIC in Q1 2018 and held it in 1 quarter. The position peaked at $560K in Q1 2018. 83 funds tracked by Wall St. Rank hold CTIC as of Q2 2018.

  • BlueCrest Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 143,587 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2018, an estimated $560K.
  • BlueCrest Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $560K in Q1 2018.
  • 83 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.